Clinical trial
Dapagliflozin on Cholesterol Metabolism in DM2: Dissecting Its Effect on Dyslipidemia by Using Stable Isotope Based Cholesterol and Glucose Fluxes
NCT03074630 is registered in ClinicalTrials.gov with Amsterdam UMC, location VUmc as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Dapagliflozin on Cholesterol Metabolism in DM2: Dissecting Its Effect on Dyslipidemia by Using Stable Isotope Based Cholesterol and Glucose Fluxes
- Lead sponsor
- Amsterdam UMC, location VUmc
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- May 31, 2016
- Completion date
- April 30, 2018
- Enrollment
- 12 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.